Table 1. —
Results of the Cell Viability Assays
| Treatment | Time 1, h | Cell Line | Average of IC50, E-6 | SD of IC50, E-6 |
|---|---|---|---|---|
| Carboplatin | 72 | A2780S | 20.7 | 23.5 |
| HeyA8 | 295.9 | 94.0 | ||
| IGR-OV1 | 60.8 | 45.2 | ||
| M41 | 43.3 | 37.0 | ||
| M41CSR | 48.2 | 26.2 | ||
| OVCA420 | 165.8 | 33.0 | ||
| OVCA432 | 63.1 | 11.7 | ||
| OVCA433 | 270.2 | 137.6 | ||
| OVCAR5 | 89.0 | 25.0 | ||
| OVCAR8 | 60.7 | 10.6 | ||
| PEO1 | 22.9 | 16.9 | ||
| TOV-21G | 38.6 | 25.3 | ||
| TYK-nu | 9.7 | 4.8 | ||
| TYKnuCisR | 63.7 | 52.8 | ||
| Cisplatin | 72 | A2780S | 4.7 | 6.7 |
| HeyA8 | 33.1 | 45.0 | ||
| IGR-OV1 | 5.7 | 8.6 | ||
| M41 | 16.8 | 5.8 | ||
| M41CSR | 13.5 | 7.1 | ||
| OVCA420 | 13.7 | NA | ||
| OVCA432 | 1.4 | NA | ||
| OVCA433 | 8.8 | NA | ||
| OVCAR5 | 12.7 | 12.7 | ||
| OVCAR8 | 48.1 | 62.5 | ||
| PEO1 | 2.7 | 1.7 | ||
| TOV-21G | 23.1 | 26.7 | ||
| TYK-nu | 4.8 | 546.9a | ||
| TYKnuCisR | 17.7 | 11.4 |
a
E-9.
IC50 = half maximal inhibitory concentration, NA = not applicable, SD = standard deviation.